Is Supernus Pharmaceuticals stock currently undervalued?

Yes, a Discounted Cash Flow analysis suggests Supernus Pharmaceuticals stock is undervalued by 82.0%, with a fair value estimate of $252.45 per share.

What are the recent performance indicators for Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals stock has gained 24.4% year-to-date and 25.5% over the last twelve months, despite recent volatility.

What are the future cash flow projections for Supernus Pharmaceuticals?

Analysts project Supernus Pharmaceuticals' free cash flow to rise sharply to $446.8 million by the end of 2029.

Home / Business and Economy / Supernus Pharma: 82% Undervalued by DCF Analysis?

Supernus Pharma: 82% Undervalued by DCF Analysis?

25 Nov

•

Summary

Supernus Pharmaceuticals stock gained 24.4% this year.
DCF analysis indicates an 82.0% undervaluation.
Analysts project free cash flow to reach $446.8 million by 2029.

Supernus Pharma: 82% Undervalued by DCF Analysis?

Supernus Pharmaceuticals has delivered impressive returns, gaining 24.4% year-to-date and 25.5% over the past year. This performance is partly driven by positive developments in its pipeline and the FDA's favorable outlook on a key product candidate. These factors have amplified existing growth projections, attracting significant investor attention.

A rigorous Discounted Cash Flow (DCF) analysis, employing a two-stage Free Cash Flow to Equity method, estimates Supernus Pharmaceuticals' intrinsic value at $252.45 per share. This valuation model indicates the stock is currently trading at a substantial 82.0% discount, suggesting it may be significantly undervalued.

Projections show a sharp increase in free cash flow from $71.1 million to an estimated $446.8 million by the end of 2029. Further long-term forecasts extend to 2035, reflecting anticipated steady expansion. Based on this financial outlook and valuation metrics, Supernus Pharmaceuticals appears to be an attractive prospect for investors seeking undervalued opportunities.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.